20 September 2020 : Meta-Analysis
Efficacy and Toxicity of Adjuvant Therapies for High-Risk Endometrial Cancer in Stage I–III: A Systematic Review and Network Meta-Analysis
Mengyin Ao12ABCDEF, Ting Ding12BF, Dan Tang12E, Mingrong Xi12E*DOI: 10.12659/MSM.925595
Med Sci Monit 2020; 26:e925595
Table 3 SUCRA values of 7 adjuvant therapies for high-risk endometrial cancer patients under 5 outcomes.
| Interventions | SUCRA values (%) | ||||
|---|---|---|---|---|---|
| Overall survival | Progression-free survival | Distant metastasis | Local recurrence | Grade III/IV late toxicities | |
| A | 39.9 | 41.4 | 34.0 | 58.8 | 56.2 |
| B | 35.9 | 52.8 | NR | NR | 56.8 |
| C | 39.7 | ||||
| D | 52.0 | 15.3 | 54.4 | 4.9 | |
| E | 59.0 | 49.9 | 56.0 | 43.5 | |
| F | 59.9 | 66.4 | 65.1 | 85.3 | 27.3 |
| G | 27.4 | 37.4 | 19.6 | 21.7 | 56.3 |
| A – pelvic radiotherapy; B – vaginal cuff brachytherapy and chemotherapy; C – pelvic radiotherapy and chemotherapy; D – no further treatment; E – chemotherapy; F – pelvic radiotherapy and vaginal brachytherapy; G – vaginal brachytherapy. NR – not reported. | |||||